Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myeloid, Acute 2Leukemia 2Hematologic Neoplasms 2Wilms Tumor 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Primary Myelofibrosis 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 61Rituximab 60Etoposide 28fludarabine phosphate 23Prednisone 23fludarabine 22Vincristine 19Filgrastim 19Doxorubicin 19ibrutinib 16Peripheral Blood Stem Cell Transplantation 16venetoclax 15Lenalidomide 14Bortezomib 14Carboplatin 13CT-P10 13Gemcitabine 12Vorinostat 11Cytarabine 11pembrolizumab 9Radiotherapy 9Melphalan 9Magnetic Resonance Spectroscopy 9Dexamethasone 9Bendamustine Hydrochloride 9Paclitaxel 8Ifosfamide 8Cyclosporine 8Biopsy 8Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large B-Cell, Diffuse × Alemtuzumab × Clear all
NCT03132584 2019-01-14

Cyclophosphamide and Alemtuzumab In Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡